Medicine
Opinion: STAT readers on Elizabeth Holmes, cancer screening, and more
“Even if Theranos had a functioning testing machine, the economic model on which is was based would result in failure,” writes a STAT reader.
Opinion: Christina Applegate puts a face on one of the most consequential challenges in neurology
“The goal is not simply to diagnose MS faster. It is to get the diagnosis right,” writes Bruce Bebo.
Is your Medicare Advantage plan ending next year? Here's what to know
Medicare open enrollment runs through Dec. 7, and for as many as 5 million seniors, it will be important to log on and pick a new plan.
STAT+: Highly anticipated Moderna-Merck melanoma cancer vaccine data arrived early
In data released at ESMO, the Moderna-Merck personalized mRNA cancer vaccine reduced recurrence-free survival and the time until distant metastasis occurred.
STAT+: Diabetes association says ‘threat’ preceded members’ ejections, but admits policies were unclear
The American Diabetes Association has issued two explanations, two reviews and an apology over its June convention. A Friday report adds new twists.
STAT+: Patient dies in Bristol Myers Squibb autoimmune CAR-T trial
Where should the safety bar be for studies investigating CAR-T therapies for autoimmune conditions?
STAT+: Most cancer drugs approved by European regulators lack a high clinical benefit, analysis finds
Most new cancer medicines approved by European regulators over a recent four-year period do not offer high clinical benefit, a new analysis finds.
STAT+: Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials
An MS treatment from Novartis cut by a third the rates of relapses compared to a standard treatment.
Opinion: It took me 13 years to be diagnosed with MS. Christina Applegate’s misdiagnosis doesn’t surprise me
“I felt Christina Applegate’s disappointment as if it were my own — because not long ago, it was,” writes Lindsay Karp.
STAT+: Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Remembering STAT’s Helen Branswell
This week on the “The Readout LOUD” podcast, we remember our beloved colleague Helen Branswell, who died last week. We speak with colleagues, family, and public health leaders abo…
STAT+: Tango builds on Revolution Medicines’ pancreatic cancer success
As the ESMO conference kicks off, Tango's pancreatic cancer combination shows striking promise and detailed data on Moderna and Merck's cancer vaccine is released early.
Anxiety builds over Medicaid work requirements
As a Boston judge heard a challenge to Medicaid work requirements, state Medicaid directors gathered in Maryland to figure out how to implement those sweeping changes.
STAT+: Treasury proposes major restrictions to U.S. investment in Chinese biotech sector
A new Treasury Department proposal would restrict U.S. investments in Chinese biotechs, but still allows licensing deals.
STAT+: Pharmalittle: We’re reading about a cancer vaccine, an experimental pancreatic cancer drug, and more
A personalized mRNA cancer vaccine reduced the risk of disease recurrence in patients with melanoma by 42% compared to a standard treatment
STAT+: AI drug firm Pathos raises $237 million, pushing valuation to $3 billion
AI drug firm Pathos raises $237 million, a deal that brings together a big Tempus dataset, AI analysis from Pathos, and drug development from BMS.
STAT+: Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer
An experimental drug combination led to tumor responses in 82% of patients with a certain type of advanced pancreatic cancer, Tango Therapeutics reported.
One family’s story of a life-extending medicine for pancreatic cancer
Bobby Senaha was among the first patients to use daraxonrasib, a new life-extending drug for pancreatic cancer. His wife shares what those extra months meant to his family.
How a targeted drug kept one patient alive 15 years — but failed to save her friends
A lung cancer patient speaks out about her cutting-edge treatment: “Research is big on tracking survival stats, but quality of life for survivors — not so much.”
STAT reporters react to the new Elizabeth Holmes documentary
It seems everyone has a hot take on the new Elizabeth Holmes documentary, "You Can See Everything." STAT reporters went to see the film — here's their review.
Opinion: Overdose deaths have plunged. We need to know why
The humbling truth is that forces outside medical care and public health policies must be playing the biggest role in a dramatic drop in opioid overdose deaths, three health exper…
Opinion: New Medicare policies will keep important pain relief from some patients
For some people, simply putting on pants can be excruciatingly painful. New policy will put pain relief out of reach for many, doctor writes.
STAT+: State officials scrambling to implement Medicaid work requirements meet up to swap notes
What state officials scrambling to implement Medicaid work requirements shared behind closed doors at the National Association of Medicaid Directors conference.
STAT+: Alnylam says Huntington’s drug shows promise in early study
It’s yet to be seen whether Alnylam’s drug will actually slow progression of Huntington’s, but the field is lively.